{"nctId":"NCT03208985","briefTitle":"A Study of Use of EllaÂ®, an Emergency Contraceptive, Under Simulated OTC Conditions","startDateStruct":{"date":"2017-05-23","type":"ACTUAL"},"conditions":["Emergency Contraception"],"count":1270,"armGroups":[{"label":"Use Phase (Ulipristal Acetate, 30 mg)","type":"EXPERIMENTAL","interventionNames":["Drug: Use Phase (Ulipristal Acetate, 30 mg)"]}],"interventions":[{"name":"Use Phase (Ulipristal Acetate, 30 mg)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Women who are self-pay or who are willing to be self-pay for the purposes of the study and who present for emergency contraception only for their own use\n\nExclusion Criteria:\n\n* Cannot read, speak and understand English\n* Cannot see well enough to read information on the label","healthyVolunteers":true,"sex":"FEMALE","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Dosing Instances Among User Population Taken Within 120 Hours (5 Days) of Most Recent Episode of Unprotected Sex.","description":"The first primary endpoint is the proportion in which the denominator includes all dosing instances of the IP and the numerator includes all dosing instances of the IP which were taken within 120 hours (5 days) of the subject's most recent episode of unprotected sex.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"704","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Dosing Instances Among User Population in Which no More Than One Tablet Was Taken.","description":"The second primary endpoint is the proportion in which the denominator is all discrete dosing instances of the IP and the numerator includes all dosing instances where no more than one tablet was taken.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"712","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Female Selectors Who Are Not Pregnant at the Time of Selection Decision.","description":"The third primary endpoint is the proportion in which the denominator includes all females who selected to use the product (regardless of whether they purchased/used) and the numerator includes all female selectors who were not pregnant at the time of the selection decision.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"814","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":783},"commonTop":["Abdominal pain lower","Nausea","Fatigue","Urinary tract infection","Viral upper respiratory tract infection"]}}}